KalGene Pharmaceuticals Inc. is a pre-clinical stage company focused on the development of a precision engineered drug candidate KG207 to slow the progression and potentially reverse Alzheimer's. KG207 targets the direct cause of Alzheimer's disease toxic beta-amyloid oligomers with reduced risk of potentially serious side effects caused by all emerging anti-amyloid monoclonal antibody therapeutics, including the recently FDA-approved Aduhelm (aducanumab; Biogen).
| Website | http://www.kalgene.com |
| Revenue | $5.1 million |
| Employees | View employees |
| Founded | 2007 |
| Address | 945 Princess St, Kingston, Ontario K7L 3N6, CA |
| Phone | +1 604-375-4519 |
| Industry | Manufacturing General, Health Care, Biotechnology, Manufacturing, Medical, Drug Discovery, Pharmaceutical |
| Competitors | Roche, Novartis, Merck & Co., Inc., Pfizer, Bristol Myers Squibb, Genentech, Amgen, Takeda, Gilead Sciences, Lilly India +48 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular KalGene Pharmaceuticals employee's phone or email?
KalGene Pharmaceuticals Questions
The KalGene Pharmaceuticals annual revenue was $5.1 million in 2026.
KalGene Pharmaceuticals is based in Kingston, Ontario.
The NAICS codes for KalGene Pharmaceuticals are [325, 32, 3254, 32541].
The SIC codes for KalGene Pharmaceuticals are [28, 283].
